Alzamend Neuro, Inc. (ALZN) Stock Price & Analysis
Alzamend Neuro, Inc. (ALZN) — MoonshotScore 32/100 (Weak band), calculated Nov 18, 2026. Price $1.02 (-3.77%), as of the Nov 19, 2026 trading session; market cap $4.92M.
Educational signal · not a buy or sell recommendation · How to read this
Alzamend Neuro, Inc. · ALZN · NASDAQ
Alzamend Neuro, Inc. is an early clinical-stage biopharmaceutical company focused on developing novel treatments for neurodegenerative and psychiatric disorders.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · Alzamend Neuro (ALZN)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Weak quality, though the balance sheet and growth are only middling. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone. Business Quality: Thin; Financial Safety: Okay; Valuation: Fair; Growth Durability: Flat; Momentum: Quiet.
- EPS beat 5 of the last 8 reports
- Altman Z -13.08 · Piotroski F 1
Holding back: weak fundamentals
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 31 | Weak | |
| 31 | Weak | |
| 31 | Weak | |
| 31 | Weak | |
| 32 | Weak | |
| 32 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $1.02 | |
| Change on the day | -3.77% | |
| Market capitalisation | $4.92M | — |
| Shares traded on the day | 36.9K |
Price & events
Other perspectives
Council score for Alzamend Neuro (ALZN): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 16, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Alzamend Neuro (ALZN), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Alzamend Neuro, Inc. (ALZN) is listed on NASDAQ. It employs 4 people. The market values it at $4.92M.
What do the latest results show for Alzamend Neuro (ALZN)?
Short answer · as of
Against analyst estimates the company has EPS beat 5 of the last 8 reports.
What are the financial strengths and risks for Alzamend Neuro (ALZN)?
Short answer · as of
What is holding it back is weak fundamentals. The distress and quality screens read Altman Z -13.08 · Piotroski F 1. Trailing ratios: current ratio 3.01 · earnings yield -163.8%.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of -13.08 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
What should you watch next at Alzamend Neuro (ALZN)?
Short answer · as of
Analyst estimates on file carry FY2026 revenue $0.00 · EPS -2.58 · 0 analysts.
What the records here don't tell us
- The next earnings date is not yet scheduled in the calendar we read.
- No quarterly income statement is held for ALZN.
Checked against the records this page reads, on the dates shown above.
How does Alzamend Neuro compare with its peers?
Short answer
Alzamend Neuro's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $13.33 Nov 18, 2026 | $471M | 91 5-pillar Nov 18, 2026 | |
| $9.07 Nov 19, 2026 | $540M | 91 5-pillar Nov 18, 2026 | |
| $3.06 Nov 19, 2026 | $258M | 90 5-pillar Nov 18, 2026 | |
| $42.53 Nov 18, 2026 | $801M | 88 5-pillar Nov 18, 2026 | |
| $15.26 Nov 18, 2026 | $85.5M | 82 5-pillar Nov 18, 2026 | |
| $11.25 Nov 18, 2026 | $102M | 82 5-pillar Nov 18, 2026 | |
| $3.89 Nov 18, 2026 | $169M | 72 5-pillar Nov 18, 2026 | |
| $1.88 Nov 19, 2026 | $178M | 69 5-pillar Nov 18, 2026 | |
| $12.17 Nov 19, 2026 | $861M | 69 5-pillar Nov 18, 2026 | |
| $9.28 Nov 19, 2026 | $545M | 68 5-pillar Nov 18, 2026 | |
| $30.78 Nov 19, 2026 | $1.03B | 64 5-pillar Nov 18, 2026 | |
| $8.14 Nov 19, 2026 | $796M | 63 5-pillar Nov 18, 2026 | |
| Alzamend Neuro (ALZN) — this page | $1.02 | $4.92M | 32 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Revenue estimate
- $0.00
- EPS estimate
- $-2.58
Measured against a quoted price of $1.02 (as of Nov 19, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Aug 26, 2026
- Transactions
- 4
- Identified insiders
- 2
- Purchases
- 0
- Sales
- 1
- Other transactions
- 3
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held ALZN in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported ALZN in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Alzamend Neuro (ALZN)?
Alzamend Neuro Stock: Key Questions Answered
These answers are editorial: they are written from question templates that restate figures shown above. They are not part of the source register.
What does the MoonshotScore mean for ALZN?
ALZN carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Is ALZN a good stock to buy?
Stock Expert AI does not rate ALZN buy, sell or hold. Alzamend Neuro, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the ALZN stock price today?
The last price recorded for Alzamend Neuro, Inc. (ALZN), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the key factors to evaluate for ALZN?
Alzamend Neuro, Inc. (ALZN) holds a MoonshotScore in the low range. Alzamend Neuro, Inc. does not currently pay a dividend, consistent with a growth-focused biopharmaceutical company reinvesting in R&D. Not financial advice.
How frequently does ALZN data refresh on this page?
ALZN's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven ALZN's recent stock price performance?
Alzamend Neuro, Inc. (ALZN) moves on earnings results, analyst revisions, sector rotation, and market sentiment. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ALZN overvalued or undervalued right now?
Alzamend Neuro, Inc. (ALZN) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of ALZN?
Fractional-share availability for Alzamend Neuro, Inc. (ALZN) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.
How can I track ALZN's earnings and financial reports?
Alzamend Neuro, Inc. (ALZN) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for ALZN earnings announcements.
Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 14 figures on this page — 6 from Financial Modeling Prep (FMP), 7 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com